BioSyent Releases Financial Results for Q2 and H1 2025

About this update from Biosyent Inc.

[{"type":"text","content":"BioSyent Releases Financial Results for Q2 and H1 2025\n\n\n\n MISSISSAUGA, Ontario, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q2) and six months (H1) ended June 30, 2025. Key highlights include:\n \n\n\n\n (CAD)\n \n\n\n Q2 2025\n \n\n\n\n\n\n % Change\n \n vs.\n \n\n\n Q2 2024\n \n\n\n\n\n\n H1 2025\n \n\n\n\n\n\n % Change\n \n vs.\n \n\n\n H1 2024\n \n\n\n\n\n\n Trailing Twelve\n \n Months\n \n (TTM)\n \n June 30, 2025\n \n\n\n\n\n\n % Change\n \n vs.\n \n\n\n TTM\n \n June 30, 2024\n \n\n\n\n\n\n\n\n Canadian Pharma Sales\n \n\n\n\n 9,327,224\n \n\n\n\n\n\n +9%\n \n\n\n\n\n\n 18,486,876\n \n\n\n\n\n\n +15%\n \n\n\n\n\n\n 35,336,401\n \n\n\n\n\n\n +12%\n \n\n\n\n\n\n\n\n International Pharma Sales\n \n\n\n\n 445,614\n \n\n\n\n\n\n +183%\n \n\n\n\n\n\n 1,980,830\n \n\n\n\n\n\n +1160%\n \n\n\n\n\n\n 2,753,588\n \n\n\n\n\n\n 129%\n \n\n\n\n\n\n\n\n Total Company Sales\n \n\n\n\n 10,179,296\n \n\n\n\n\n\n +14%\n \n\n\n\n\n\n 21,158,256\n \n\n\n\n\n\n +27%\n \n\n\n\n\n\n 39,510,951\n \n\n\n\n\n\n +17%\n \n\n\n\n\n\n\n\n EBITDA\n \n\n\n 1\n \n\n\n\n\n 2,760,149\n \n\n\n\n\n\n +35%\n \n\n\n\n\n\n 5,961,796\n \n\n\n\n\n\n +40%\n \n\n\n\n\n\n 11,052,544\n \n\n\n\n\n\n +26%\n \n\n\n\n\n\n\n\n Net Income After Taxes (NIAT)\n \n\n\n\n 2,018,171\n \n\n\n\n\n\n +28%\n \n\n\n\n\n\n 4,338,104\n \n\n\n\n\n\n +30%\n \n\n\n\n\n\n 8,259,192\n \n\n\n\n\n\n +16%\n \n\n\n\n\n\n\n\n Fully Diluted EPS\n \n\n\n\n 0.18\n \n\n\n\n\n\n +31%\n \n\n\n\n\n\n 0.38\n \n\n\n\n\n\n +33%\n \n\n\n\n\n\n 0.72\n \n\n\n\n\n\n +20%\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Return on Average Equity for TTM June 30, 2025 was 23% as compared to 21% for TTM June 30, 2024\n \n\n During H1 2025, repurchased for cancellation a total of 19,500 common shares under a Normal Course Issuer Bid (NCIB)\n \n\n Paid quarterly cash dividends of $0.05 per common share on March 14, 2025 and June 13, 2025\n \n\n Declared subsequent cash dividend of $0.05 per common share to be paid on September 15, 2025\n \n\n\n “Each of our Canadian Pharma, International Pharma, and Legacy businesses continued to perform well during Q2 2025, delivering 14% sales growth and 28% net profit growth overall,” commented Mr. René Goehrum, President an...

More updates from Biosyent Inc.